CD274 and breast carcinoma: The MEDIOLA study, a phase II clinical trial that explores the effective combination of Olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 mAb) in the treatment of advanced solid tumors including TN breast cancer has already delivered encouraging results [48].